China-based Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd (HKG: 1349, SHA: 688505) announced that a Phase I clinical trial filing for its topical JAK1 selective inhibitor FZJ-003 gel (specification: 1%, 2%) in atopic dermatitis (AD) has been accepted for review.
Global JAK Inhibitor Market
Globally, nine JAK inhibitors are currently marketed, including Sanofi/Incyte’s ruxolitinib, Eli Lilly’s baricitinib, Pfizer’s tofacitinib, Astellas’ peficitinib, and Japan Tobacco’s delgocitinib, all first-generation JAK inhibitors. Second-generation JAK inhibitors include Celgene’s fedratinib, AbbVie’s upadacitinib, Gilead’s filgotinib, and Pfizer’s abrocitinib. Among these, tofacitinib, ruxolitinib, and baricitinib are available in China, with only ruxolitinib offered in a topical formulation.
Market Outlook
The JAK market in China, valued at RMB 292 million in 2020, is projected to reach RMB 10 billion in 2024 and RMB 48.1 billion in 2030, with a compound growth rate of 92.2% forecast from 2019 to 2024.
Development Landscape
There are 294 investigational JAK inhibitors globally, with the majority being second-generation selective inhibitors. In China, Hengrui Medicine and Zelgen Bio lead the pack with products in Phase III development.-Fineline Info & Tech
